CA3168643A1 - Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition - Google Patents

Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition

Info

Publication number
CA3168643A1
CA3168643A1 CA3168643A CA3168643A CA3168643A1 CA 3168643 A1 CA3168643 A1 CA 3168643A1 CA 3168643 A CA3168643 A CA 3168643A CA 3168643 A CA3168643 A CA 3168643A CA 3168643 A1 CA3168643 A1 CA 3168643A1
Authority
CA
Canada
Prior art keywords
polypeptide
arginine
lysine
bacteria
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168643A
Other languages
English (en)
French (fr)
Inventor
Yeong Min Park
Yangmee Kim
In Duk Jung
Seung-Hyun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HLB Science Inc
Original Assignee
Dandi Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200023629A external-priority patent/KR102368983B1/ko
Application filed by Dandi Bioscience Inc filed Critical Dandi Bioscience Inc
Publication of CA3168643A1 publication Critical patent/CA3168643A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3168643A 2019-02-28 2020-02-27 Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition Pending CA3168643A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190023534 2019-02-28
KR10-2019-0023534 2019-02-28
KR10-2020-0023629 2020-02-26
KR1020200023629A KR102368983B1 (ko) 2019-02-28 2020-02-26 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
PCT/KR2020/002826 WO2020175936A1 (ko) 2019-02-28 2020-02-27 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물

Publications (1)

Publication Number Publication Date
CA3168643A1 true CA3168643A1 (en) 2020-09-03

Family

ID=72239598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168643A Pending CA3168643A1 (en) 2019-02-28 2020-02-27 Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition

Country Status (5)

Country Link
US (1) US12371453B2 (https=)
JP (1) JP7219512B2 (https=)
BR (1) BR112021016996A8 (https=)
CA (1) CA3168643A1 (https=)
WO (1) WO2020175936A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118406113A (zh) * 2024-05-10 2024-07-30 东北农业大学 具有lps结合能力的靶向革兰氏阴性菌的抗菌肽及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298197A (zh) * 2020-03-20 2022-11-04 Hlb科学株式会社 用于去除脂多糖的组合物和试剂盒
CN115960171B (zh) * 2022-10-12 2023-08-29 东北农业大学 高稳定性Trp-pocket跨链交互型β-发卡抗菌肽及制备方法和应用
CN120865346A (zh) * 2024-04-26 2025-10-31 深圳碳云智肽药物科技有限公司 小分子抗菌多肽、制备方法及其应用
CN118955633B (zh) * 2024-07-19 2025-05-09 东北农业大学 富含D-Arg的抗酶解十四肽2rrr及其制备方法和应用
CN118667035A (zh) * 2024-07-24 2024-09-20 兰州大学 一类抗菌基序修饰的广谱低耐药抗菌肽及其应用
CN119591691B (zh) * 2025-01-10 2025-10-21 福建农林大学 基于大黄鱼cxcl8蛋白的抗菌肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608277B2 (en) * 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
EP2214656B1 (en) * 2007-10-26 2018-12-05 Avivagen Inc. Compositions and methods for enhancing immune response
US8440794B2 (en) 2008-10-05 2013-05-14 Universita' Degli Studi Di Siena Peptide sequences, their branched form and use thereof for antimicrobial applications
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
NZ764564A (en) * 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions
MX384716B (es) 2014-01-29 2025-03-14 Enzymatica Ab Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.
JP6338899B2 (ja) 2014-03-18 2018-06-06 国立研究開発法人産業技術総合研究所 両生類ネッタイツメガエル皮膚由来機能性ペプチド
KR101477795B1 (ko) 2014-04-23 2015-01-02 건국대학교 산학협력단 Ａｄｋ 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
KR101785050B1 (ko) 2014-12-10 2017-10-13 건국대학교 글로컬산학협력단 Ａｄｋ 단백질 및 항생제를 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
JP6475865B2 (ja) 2015-04-03 2019-02-27 コングク ユニバーシティ グローカル インダストリー−アカデミック コラボレーション ファウンデーション Ａｄｋたんぱく質を有効成分として含むカルバペネム耐性グラム陰性菌に対する抗菌用の組成物
JP2018529689A (ja) 2015-09-17 2018-10-11 ソウル大学校産学協力団Ｓｅｏｕｌ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ グラム陰性菌に対する抗菌活性を示す切断または折り畳まれたヘリックスペプチドまたはペプチド類似体およびその用途
KR101792239B1 (ko) * 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물
EP3638721A1 (en) 2017-06-16 2020-04-22 Borealis AG A polymer composition for photovoltaic applications
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
KR102011676B1 (ko) 2017-08-29 2019-08-19 (주) 한성스틸 벽난로
CN115298197A (zh) * 2020-03-20 2022-11-04 Hlb科学株式会社 用于去除脂多糖的组合物和试剂盒
KR102709142B1 (ko) * 2020-08-27 2024-09-26 에이치엘비사이언스 주식회사 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118406113A (zh) * 2024-05-10 2024-07-30 东北农业大学 具有lps结合能力的靶向革兰氏阴性菌的抗菌肽及其制备方法和应用
CN118406113B (zh) * 2024-05-10 2025-04-22 东北农业大学 具有lps结合能力的靶向革兰氏阴性菌的抗菌肽及其制备方法和应用

Also Published As

Publication number Publication date
US12371453B2 (en) 2025-07-29
JP2022521543A (ja) 2022-04-08
BR112021016996A8 (pt) 2022-11-22
BR112021016996A2 (https=) 2021-11-30
WO2020175936A1 (ko) 2020-09-03
US20220144892A1 (en) 2022-05-12
JP7219512B2 (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
AU2020227591B2 (en) Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
US12371453B2 (en) Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
AU758698B2 (en) Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
AU2007229275B2 (en) Antimicrobial protein
JP7315724B2 (ja) リシン置換を含むＲｏｍｏ１由来抗菌ペプチドおよびその変異体
KR102224929B1 (ko) 해삼에서 분리한 항균 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도
JP2001503020A (ja) 広域抗菌活性を有する環状ペプチド
KR102415734B1 (ko) 신규한 항균 펩타이드 및 이의 용도
CN115397836A (zh) 新型抗菌肽及其用途
US7745390B2 (en) Antimicrobial peptides
RU2797347C2 (ru) Полипептид, обладающий антибактериальной активностью, композиция для профилактики или лечения сепсиса, которая включает его, и антибактериальная композиция
WO2012033450A1 (en) Novel antimicrobial peptides
JP3661549B2 (ja) 抗菌及び抗真菌ペプチド
JP2019523211A (ja) 病原菌に対する抗生活性を有するペプチド及びこれを含む抗生ペプチド組成物
US20190352339A1 (en) Peptide inhibitor of transmembrane pore formation and effluxpump function in a small multidrug resistance protein from pseudomonas aeruginosa
KR102451854B1 (ko) 신규한 항균 펩타이드 h103 및 이의 용도
KR102496847B1 (ko) 흰점박이꽃무지 유충으로부터 분리한 프로테티아마이신-5 펩타이드 및 이의 용도
KR102492397B1 (ko) 흰점박이꽃무지 유충으로부터 분리한 프로테티아마이신-4 펩타이드 및 이의 용도
WO2011115562A1 (en) Antimicrobial compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220726

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250801

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250905

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260223